Article : https://pmc.ncbi.nlm.nih.gov/articles/PMC12399406/

Citation: Chen J, Zhang Q, Wu Q, Zhang X, Xiang Z, Zhu S, Dai T, Si Y. Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials. J Diabetes. 2025 Sep;17(9):e70151. doi: 10.1111/1753-0407.70151. PMID: 40887719; PMCID: PMC12399406.

Title: Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials.

This meta-analysis of 25 randomized controlled trials (RCTs) involving over 81,000 participants provides critical data for psychiatrists regarding the safety profile of GLP-1 receptor agonists (GLP-1 RAs) in relation to suicidal behavior.

Key Take-Home Messages

  • No Significant Association with Suicidality: The pooled analysis found no significant difference in the incidence of suicidal behavior between those using GLP-1 RAs and control groups (RR = 0.84).
  • Broad Safety Across Outcomes: There were no statistically significant increases across any specific category of suicidal behavior, including suicidal ideation, suicide attempts, depression-related suicides, or completed suicides.
  • Consistency Across Populations: The lack of association remained consistent regardless of whether the patient was being treated for type 2 diabetes (T2DM) or obesity, and notably, held true for both adults and adolescents.
  • Agent-Specific Neutrality: Subgroup analyses for individual agents—including semaglutide, liraglutide, dulaglutide, and exenatide—all showed no significant correlation with suicidal behavior.

Neurobiological Insights for the Psychiatrist

The sources highlight a complex “double-edged” biological mechanism that may explain conflicting reports in clinical literature:

  • The Paradox of Acute vs. Chronic Activation: Acute central administration of GLP-1 RAs in animal models can actually be anxiogenic, increasing serotonin turnover in the amygdala and potentially inducing negative emotions.
  • Chronic Antidepressant Potential: Conversely, chronic administration has shown antidepressant-like effects in animal models. This is likely mediated by anti-inflammatory mechanisms, such as reducing neuroinflammation and protecting neural cells from oxidative stress.
  • Hypothalamic Influence: While GLP-1 RAs can increase certain inflammatory mediators (like IL-6) in the brain to suppress appetite, the meta-analysis suggests these pathways do not translate into clinically significant behavioral risks for suicide in human patients.

Clinical Practice Applications

  • Reconciling Depression and Suicide Risks: While our previous discussion noted a small increase in incident depression in real-world data, this meta-analysis of RCTs suggests that this risk does not currently extend to suicidal behavior. Psychiatrists should distinguish between the potential for low-grade mood changes and the more severe risk of suicidality.
  • Baseline Risk Awareness: It is essential to remember that obesity and T2DM are independent risk factors for suicide due to chronic inflammation, HPA axis dysfunction, and psychosocial stressors like weight stigma. Any mood changes observed may be related to the underlying condition rather than the medication itself.
  • Vigilance in Vulnerable Groups: Although the data is reassuring for adolescents, they remain a high-risk group for suicidal ideation generally (prevalence of 15%–25%). Psychiatrists should maintain standard monitoring for this population when they are prescribed GLP-1 RAs for obesity.
  • Informed Consent and Monitoring: Despite the reassuring findings of this meta-analysis, the authors note that statistical power can be limited for rare events like suicide. Therefore, continued routine monitoring for mood and behavioral changes remains a best practice in psychiatric care for patients on these agents.